Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 84 | 2024 | 22131 | 4.520 |
Why?
|
Survivors | 40 | 2024 | 2372 | 3.580 |
Why?
|
Medical Oncology | 19 | 2022 | 2317 | 1.850 |
Why?
|
Primary Health Care | 17 | 2024 | 4668 | 1.460 |
Why?
|
Breast Neoplasms | 52 | 2022 | 20988 | 1.410 |
Why?
|
Physicians, Primary Care | 4 | 2023 | 617 | 1.240 |
Why?
|
Mammography | 12 | 2020 | 2430 | 1.200 |
Why?
|
Continuity of Patient Care | 7 | 2023 | 1066 | 1.190 |
Why?
|
Patient Education as Topic | 13 | 2020 | 2315 | 0.900 |
Why?
|
Head and Neck Neoplasms | 4 | 2022 | 2894 | 0.890 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2022 | 9277 | 0.870 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 9 | 2017 | 926 | 0.860 |
Why?
|
Delivery of Health Care | 18 | 2024 | 5332 | 0.830 |
Why?
|
Patient Care Planning | 7 | 2019 | 905 | 0.790 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2020 | 940 | 0.770 |
Why?
|
Patient Preference | 6 | 2022 | 925 | 0.750 |
Why?
|
Dental Care | 1 | 2024 | 285 | 0.740 |
Why?
|
Delayed Diagnosis | 4 | 2020 | 463 | 0.740 |
Why?
|
Patient Acceptance of Health Care | 9 | 2018 | 3194 | 0.710 |
Why?
|
Decision Making | 10 | 2020 | 3918 | 0.680 |
Why?
|
Patient-Centered Care | 5 | 2024 | 1418 | 0.670 |
Why?
|
Neoplasms, Second Primary | 6 | 2023 | 1051 | 0.660 |
Why?
|
Humans | 177 | 2024 | 760617 | 0.640 |
Why?
|
Long-Term Care | 4 | 2017 | 631 | 0.610 |
Why?
|
Quality of Life | 17 | 2024 | 13347 | 0.600 |
Why?
|
Health Services Accessibility | 5 | 2024 | 5430 | 0.590 |
Why?
|
Narration | 1 | 2019 | 218 | 0.570 |
Why?
|
Telemedicine | 5 | 2022 | 3050 | 0.560 |
Why?
|
Physical Endurance | 1 | 2019 | 366 | 0.550 |
Why?
|
Aftercare | 2 | 2019 | 913 | 0.530 |
Why?
|
Mastectomy, Segmental | 5 | 2017 | 955 | 0.530 |
Why?
|
Quality of Health Care | 6 | 2024 | 4321 | 0.530 |
Why?
|
Attitude of Health Personnel | 9 | 2019 | 3879 | 0.520 |
Why?
|
Deductibles and Coinsurance | 4 | 2019 | 316 | 0.510 |
Why?
|
Communication | 7 | 2018 | 3849 | 0.500 |
Why?
|
Workflow | 1 | 2020 | 849 | 0.500 |
Why?
|
Running | 1 | 2019 | 488 | 0.470 |
Why?
|
Attitude to Health | 3 | 2019 | 2024 | 0.470 |
Why?
|
Mass Screening | 8 | 2020 | 5424 | 0.470 |
Why?
|
Early Detection of Cancer | 10 | 2024 | 3196 | 0.470 |
Why?
|
General Practitioners | 1 | 2014 | 90 | 0.430 |
Why?
|
Practice Guidelines as Topic | 8 | 2024 | 7389 | 0.410 |
Why?
|
Breast Self-Examination | 2 | 2002 | 33 | 0.400 |
Why?
|
Patient Participation | 6 | 2020 | 1443 | 0.400 |
Why?
|
United States | 36 | 2024 | 72272 | 0.390 |
Why?
|
Referral and Consultation | 3 | 2020 | 3599 | 0.390 |
Why?
|
Insurance Coverage | 4 | 2018 | 1937 | 0.390 |
Why?
|
Patient Care Management | 2 | 2017 | 302 | 0.390 |
Why?
|
Medical Indigency | 1 | 2011 | 63 | 0.390 |
Why?
|
Internal Medicine | 3 | 2021 | 1051 | 0.360 |
Why?
|
Appointments and Schedules | 1 | 2014 | 442 | 0.360 |
Why?
|
Mastectomy | 7 | 2008 | 1817 | 0.360 |
Why?
|
Evidence-Based Medicine | 4 | 2019 | 3680 | 0.350 |
Why?
|
Population Surveillance | 2 | 2020 | 2595 | 0.350 |
Why?
|
Ovarian Neoplasms | 2 | 2022 | 4849 | 0.340 |
Why?
|
Evidence-Based Practice | 1 | 2014 | 494 | 0.340 |
Why?
|
Physicians | 4 | 2019 | 4583 | 0.340 |
Why?
|
Pandemics | 6 | 2022 | 8645 | 0.340 |
Why?
|
Insurance, Health | 5 | 2019 | 2495 | 0.340 |
Why?
|
Employment | 1 | 2016 | 1113 | 0.340 |
Why?
|
Palliative Care | 4 | 2024 | 3592 | 0.330 |
Why?
|
Medication Adherence | 2 | 2011 | 2174 | 0.330 |
Why?
|
Female | 94 | 2024 | 392148 | 0.330 |
Why?
|
Terminal Care | 1 | 2021 | 1755 | 0.330 |
Why?
|
Clinical Competence | 3 | 2023 | 4789 | 0.320 |
Why?
|
Physician-Patient Relations | 7 | 2016 | 3239 | 0.320 |
Why?
|
Survival Rate | 8 | 2017 | 12719 | 0.310 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2014 | 1084 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3088 | 0.310 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2533 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3209 | 0.310 |
Why?
|
Vulvar Neoplasms | 2 | 2024 | 263 | 0.300 |
Why?
|
Patient Compliance | 4 | 2014 | 2688 | 0.300 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2014 | 4007 | 0.300 |
Why?
|
Uterine Neoplasms | 3 | 2023 | 1420 | 0.290 |
Why?
|
Patient Care Team | 3 | 2017 | 2515 | 0.290 |
Why?
|
Tamoxifen | 2 | 2011 | 965 | 0.290 |
Why?
|
Aromatase Inhibitors | 1 | 2011 | 513 | 0.290 |
Why?
|
Patient Satisfaction | 6 | 2021 | 3451 | 0.280 |
Why?
|
Women's Health | 4 | 2009 | 2065 | 0.280 |
Why?
|
Physicians, Family | 1 | 2009 | 348 | 0.280 |
Why?
|
Carcinoma in Situ | 2 | 2009 | 791 | 0.270 |
Why?
|
Middle Aged | 62 | 2024 | 220584 | 0.270 |
Why?
|
Fear | 3 | 2020 | 1477 | 0.270 |
Why?
|
Breast | 4 | 2019 | 1963 | 0.270 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 955 | 0.270 |
Why?
|
Adaptation, Psychological | 6 | 2022 | 2629 | 0.260 |
Why?
|
Aged | 50 | 2024 | 169042 | 0.260 |
Why?
|
Adult | 52 | 2024 | 220969 | 0.260 |
Why?
|
Research | 5 | 2023 | 1977 | 0.250 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2018 | 1520 | 0.240 |
Why?
|
Interdisciplinary Communication | 2 | 2014 | 928 | 0.240 |
Why?
|
Lymphoma | 1 | 2014 | 1899 | 0.240 |
Why?
|
Health Promotion | 1 | 2017 | 2206 | 0.240 |
Why?
|
Nomograms | 3 | 2015 | 230 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2023 | 2020 | 0.240 |
Why?
|
Internet | 3 | 2014 | 3090 | 0.230 |
Why?
|
Patient Care | 1 | 2009 | 621 | 0.230 |
Why?
|
Endometrial Neoplasms | 3 | 2023 | 1365 | 0.220 |
Why?
|
Women | 1 | 2005 | 224 | 0.220 |
Why?
|
Prostatic Neoplasms | 4 | 2020 | 11106 | 0.220 |
Why?
|
Estrogen Replacement Therapy | 2 | 2009 | 1208 | 0.220 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1191 | 0.220 |
Why?
|
Health Services Research | 4 | 2021 | 1808 | 0.220 |
Why?
|
Drug Costs | 1 | 2011 | 1183 | 0.210 |
Why?
|
Health Expenditures | 4 | 2018 | 2361 | 0.200 |
Why?
|
Carcinosarcoma | 1 | 2023 | 106 | 0.200 |
Why?
|
Physical Examination | 1 | 2008 | 1254 | 0.200 |
Why?
|
Carcinoma, Endometrioid | 2 | 2023 | 276 | 0.200 |
Why?
|
Documentation | 1 | 2008 | 895 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 36402 | 0.190 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 26049 | 0.190 |
Why?
|
Policy | 2 | 2023 | 506 | 0.190 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2023 | 217 | 0.190 |
Why?
|
Health Maintenance Organizations | 3 | 2009 | 658 | 0.170 |
Why?
|
Latin America | 1 | 2021 | 407 | 0.170 |
Why?
|
Erythema Nodosum | 1 | 2000 | 32 | 0.170 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2000 | 71 | 0.170 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13635 | 0.170 |
Why?
|
Neoplasm Staging | 11 | 2019 | 11116 | 0.170 |
Why?
|
Aged, 80 and over | 22 | 2020 | 58894 | 0.170 |
Why?
|
Managed Care Programs | 3 | 2014 | 937 | 0.160 |
Why?
|
Young Adult | 11 | 2022 | 59179 | 0.160 |
Why?
|
Oral Health | 1 | 2024 | 492 | 0.150 |
Why?
|
Education, Continuing | 1 | 2019 | 114 | 0.150 |
Why?
|
Needs Assessment | 3 | 2018 | 1139 | 0.150 |
Why?
|
Reproduction | 1 | 2023 | 645 | 0.150 |
Why?
|
Sensitivity and Specificity | 7 | 2024 | 14648 | 0.150 |
Why?
|
Psychotherapy, Group | 1 | 2002 | 413 | 0.150 |
Why?
|
Mental Processes | 1 | 2019 | 243 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2023 | 709 | 0.150 |
Why?
|
Life Style | 2 | 2020 | 3904 | 0.150 |
Why?
|
Male | 32 | 2024 | 360358 | 0.140 |
Why?
|
Hypothyroidism | 1 | 2022 | 667 | 0.140 |
Why?
|
Depression | 5 | 2023 | 8132 | 0.130 |
Why?
|
Critical Pathways | 1 | 2020 | 474 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
Health Services Needs and Demand | 3 | 2019 | 1400 | 0.130 |
Why?
|
Oral Hygiene | 1 | 2017 | 132 | 0.130 |
Why?
|
Hot Flashes | 2 | 2009 | 330 | 0.130 |
Why?
|
Attitude | 2 | 2014 | 772 | 0.130 |
Why?
|
Longitudinal Studies | 5 | 2019 | 14591 | 0.130 |
Why?
|
Models, Theoretical | 2 | 2010 | 3567 | 0.130 |
Why?
|
Papillomavirus Infections | 2 | 2019 | 1611 | 0.130 |
Why?
|
Europe | 1 | 2022 | 3413 | 0.130 |
Why?
|
Curriculum | 2 | 2021 | 3738 | 0.120 |
Why?
|
Health Surveys | 5 | 2019 | 4037 | 0.120 |
Why?
|
Delphi Technique | 3 | 2024 | 846 | 0.120 |
Why?
|
Health Care Surveys | 4 | 2016 | 2423 | 0.120 |
Why?
|
Forecasting | 2 | 2017 | 2924 | 0.120 |
Why?
|
Information Dissemination | 1 | 2023 | 1125 | 0.120 |
Why?
|
China | 1 | 2020 | 2374 | 0.120 |
Why?
|
Professional Role | 1 | 2017 | 313 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3514 | 0.110 |
Why?
|
Consumer Health Information | 1 | 2016 | 215 | 0.110 |
Why?
|
SEER Program | 3 | 2014 | 1450 | 0.110 |
Why?
|
Consensus | 3 | 2022 | 3117 | 0.110 |
Why?
|
Anxiety | 4 | 2023 | 4570 | 0.110 |
Why?
|
Quality Assurance, Health Care | 2 | 2014 | 2164 | 0.110 |
Why?
|
Vulnerable Populations | 1 | 2019 | 704 | 0.110 |
Why?
|
Educational Status | 1 | 2021 | 2509 | 0.110 |
Why?
|
Medicare | 1 | 2011 | 6765 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2019 | 1469 | 0.110 |
Why?
|
Healthcare Disparities | 2 | 2020 | 3351 | 0.100 |
Why?
|
Health Personnel | 4 | 2019 | 3333 | 0.100 |
Why?
|
Osteoporosis | 1 | 2022 | 1604 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 2020 | 1438 | 0.100 |
Why?
|
Boston | 3 | 2011 | 9313 | 0.100 |
Why?
|
Cohort Studies | 10 | 2019 | 41457 | 0.100 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39063 | 0.100 |
Why?
|
Adolescent | 12 | 2024 | 88234 | 0.100 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1896 | 0.100 |
Why?
|
Caregivers | 3 | 2022 | 2241 | 0.100 |
Why?
|
Developing Countries | 1 | 2024 | 2867 | 0.100 |
Why?
|
Data Collection | 2 | 2012 | 3315 | 0.090 |
Why?
|
American Cancer Society | 2 | 2022 | 69 | 0.090 |
Why?
|
Exercise | 4 | 2022 | 5886 | 0.090 |
Why?
|
Self Report | 2 | 2020 | 3723 | 0.090 |
Why?
|
Anthracyclines | 1 | 2012 | 285 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1800 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2020 | 1998 | 0.090 |
Why?
|
Postmenopause | 2 | 2009 | 2511 | 0.090 |
Why?
|
Risk Assessment | 8 | 2024 | 23972 | 0.080 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 97 | 0.080 |
Why?
|
Pilot Projects | 4 | 2024 | 8618 | 0.080 |
Why?
|
Socioeconomic Factors | 5 | 2018 | 7798 | 0.080 |
Why?
|
Insurance Claim Review | 1 | 2014 | 741 | 0.080 |
Why?
|
Comorbidity | 3 | 2020 | 10505 | 0.080 |
Why?
|
Group Practice, Prepaid | 1 | 2008 | 15 | 0.080 |
Why?
|
Neoplasm Invasiveness | 5 | 2017 | 3593 | 0.080 |
Why?
|
Current Procedural Terminology | 1 | 2009 | 89 | 0.080 |
Why?
|
Pregnancy Complications | 3 | 2000 | 2948 | 0.080 |
Why?
|
Health Behavior | 2 | 2018 | 2643 | 0.080 |
Why?
|
Drug Substitution | 1 | 2011 | 290 | 0.080 |
Why?
|
Washington | 1 | 2009 | 315 | 0.080 |
Why?
|
Interprofessional Relations | 2 | 2014 | 990 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2024 | 5812 | 0.070 |
Why?
|
Melanoma | 2 | 2024 | 5697 | 0.070 |
Why?
|
Risk Factors | 13 | 2018 | 74115 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3244 | 0.070 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2017 | 1187 | 0.070 |
Why?
|
Prognosis | 8 | 2016 | 29600 | 0.070 |
Why?
|
Disease Progression | 2 | 2022 | 13495 | 0.070 |
Why?
|
Genetic Counseling | 1 | 2011 | 627 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6174 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4910 | 0.070 |
Why?
|
Genital Neoplasms, Female | 2 | 2024 | 532 | 0.070 |
Why?
|
Time Factors | 4 | 2018 | 39913 | 0.070 |
Why?
|
Community Health Services | 1 | 2011 | 654 | 0.060 |
Why?
|
Intention | 1 | 2008 | 346 | 0.060 |
Why?
|
Psychometrics | 1 | 2015 | 3060 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 1784 | 0.060 |
Why?
|
Gynecology | 2 | 2010 | 526 | 0.060 |
Why?
|
Inservice Training | 1 | 2008 | 375 | 0.060 |
Why?
|
Professional Practice | 1 | 2007 | 313 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2017 | 2056 | 0.060 |
Why?
|
Phenotype | 1 | 2023 | 16571 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2023 | 64568 | 0.060 |
Why?
|
Registries | 4 | 2019 | 8207 | 0.060 |
Why?
|
Colorectal Neoplasms | 2 | 2014 | 6925 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3238 | 0.060 |
Why?
|
Hormone Replacement Therapy | 1 | 2010 | 750 | 0.060 |
Why?
|
Child | 7 | 2024 | 80079 | 0.060 |
Why?
|
Obstetrics | 2 | 2010 | 666 | 0.060 |
Why?
|
Biopsy | 4 | 2019 | 6762 | 0.060 |
Why?
|
Medical History Taking | 1 | 2008 | 773 | 0.060 |
Why?
|
Ethics Committees, Research | 1 | 2005 | 196 | 0.060 |
Why?
|
International Classification of Diseases | 1 | 2009 | 909 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2009 | 2925 | 0.060 |
Why?
|
Paget Disease, Extramammary | 1 | 2024 | 51 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3426 | 0.050 |
Why?
|
Incidence | 4 | 2018 | 21337 | 0.050 |
Why?
|
Life Expectancy | 1 | 2010 | 1239 | 0.050 |
Why?
|
Physician's Role | 1 | 2009 | 917 | 0.050 |
Why?
|
Qualitative Research | 2 | 2013 | 3016 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11736 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2008 | 724 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9026 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20074 | 0.050 |
Why?
|
International Educational Exchange | 1 | 2002 | 49 | 0.050 |
Why?
|
Computers, Handheld | 1 | 2024 | 210 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2014 | 1948 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 2553 | 0.050 |
Why?
|
California | 2 | 2020 | 1430 | 0.050 |
Why?
|
Retrospective Studies | 13 | 2020 | 80566 | 0.050 |
Why?
|
Health Status | 3 | 2010 | 4075 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2017 | 3805 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4020 | 0.050 |
Why?
|
Developed Countries | 1 | 2024 | 450 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5319 | 0.050 |
Why?
|
Program Evaluation | 2 | 2019 | 2486 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2006 | 969 | 0.050 |
Why?
|
Menopause | 1 | 2009 | 1645 | 0.050 |
Why?
|
Precancerous Conditions | 1 | 2007 | 980 | 0.040 |
Why?
|
beta 2-Glycoprotein I | 1 | 2000 | 28 | 0.040 |
Why?
|
Mass Media | 1 | 2003 | 302 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9712 | 0.040 |
Why?
|
Patient Selection | 1 | 2012 | 4237 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2022 | 390 | 0.040 |
Why?
|
Internship and Residency | 1 | 2000 | 5878 | 0.040 |
Why?
|
Massachusetts | 2 | 2010 | 8833 | 0.040 |
Why?
|
Connecticut | 1 | 2000 | 364 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2010 | 2218 | 0.040 |
Why?
|
Medical Records | 1 | 2005 | 1407 | 0.040 |
Why?
|
New England | 1 | 2002 | 1051 | 0.040 |
Why?
|
Disease Management | 1 | 2010 | 2506 | 0.040 |
Why?
|
Heart Failure | 2 | 2014 | 11669 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 834 | 0.040 |
Why?
|
Problem-Based Learning | 1 | 2002 | 356 | 0.040 |
Why?
|
Case-Control Studies | 6 | 2015 | 22148 | 0.040 |
Why?
|
Age Factors | 4 | 2020 | 18381 | 0.040 |
Why?
|
Mammaplasty | 1 | 2007 | 1232 | 0.040 |
Why?
|
Family Practice | 2 | 2010 | 507 | 0.040 |
Why?
|
Logistic Models | 3 | 2018 | 13245 | 0.040 |
Why?
|
Osteitis | 1 | 1996 | 33 | 0.030 |
Why?
|
Hyperostosis | 1 | 1996 | 29 | 0.030 |
Why?
|
Survival Analysis | 2 | 2016 | 10073 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10199 | 0.030 |
Why?
|
Algorithms | 2 | 2014 | 14018 | 0.030 |
Why?
|
Quadruplets | 1 | 1996 | 9 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2000 | 978 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1202 | 0.030 |
Why?
|
Genetic Testing | 2 | 2012 | 3533 | 0.030 |
Why?
|
Odds Ratio | 3 | 2014 | 9643 | 0.030 |
Why?
|
Recurrence | 2 | 2016 | 8426 | 0.030 |
Why?
|
ROC Curve | 2 | 2014 | 3575 | 0.030 |
Why?
|
Synovitis | 1 | 1996 | 217 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13382 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2021 | 1110 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 296 | 0.030 |
Why?
|
Pregnancy | 5 | 2019 | 29868 | 0.030 |
Why?
|
Self Efficacy | 1 | 2019 | 636 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2019 | 570 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1550 | 0.030 |
Why?
|
Societies, Medical | 2 | 2019 | 3900 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2012 | 1700 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8516 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1386 | 0.030 |
Why?
|
Hysterectomy | 1 | 2019 | 856 | 0.030 |
Why?
|
MEDLINE | 1 | 2013 | 119 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 544 | 0.030 |
Why?
|
Emotions | 1 | 2005 | 2740 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1995 | 410 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1117 | 0.030 |
Why?
|
Clinical Coding | 1 | 2014 | 181 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1663 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2014 | 210 | 0.020 |
Why?
|
Glycoproteins | 1 | 2000 | 2200 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2019 | 5239 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2023 | 2723 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 421 | 0.020 |
Why?
|
Health Plan Implementation | 1 | 2014 | 335 | 0.020 |
Why?
|
Acne Vulgaris | 1 | 1996 | 349 | 0.020 |
Why?
|
Incidental Findings | 1 | 2016 | 697 | 0.020 |
Why?
|
Brachytherapy | 1 | 2019 | 1223 | 0.020 |
Why?
|
Autoantibodies | 1 | 2000 | 2115 | 0.020 |
Why?
|
Aspirin | 1 | 2022 | 3127 | 0.020 |
Why?
|
Genes, BRCA2 | 1 | 2014 | 590 | 0.020 |
Why?
|
Education, Medical | 1 | 2002 | 1724 | 0.020 |
Why?
|
Income | 1 | 2019 | 1870 | 0.020 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 753 | 0.020 |
Why?
|
Prevalence | 2 | 2019 | 15689 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17878 | 0.020 |
Why?
|
Diet | 2 | 2022 | 8048 | 0.020 |
Why?
|
Professional-Family Relations | 1 | 2013 | 495 | 0.020 |
Why?
|
Dyspareunia | 1 | 2009 | 47 | 0.020 |
Why?
|
Medical Audit | 1 | 2010 | 453 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 202 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 678 | 0.020 |
Why?
|
Psoriasis | 1 | 1996 | 944 | 0.020 |
Why?
|
Health Resources | 1 | 2014 | 933 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1779 | 0.020 |
Why?
|
Sweating | 1 | 2009 | 155 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2000 | 4533 | 0.020 |
Why?
|
Patient Transfer | 1 | 2014 | 793 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2014 | 2897 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1892 | 0.020 |
Why?
|
Poverty | 1 | 2019 | 2692 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5061 | 0.020 |
Why?
|
Awareness | 1 | 2011 | 649 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2871 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2012 | 2509 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6340 | 0.020 |
Why?
|
Complementary Therapies | 1 | 2010 | 486 | 0.020 |
Why?
|
Skin | 1 | 2000 | 4473 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9604 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2332 | 0.020 |
Why?
|
Postal Service | 1 | 2005 | 96 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2899 | 0.010 |
Why?
|
Peer Group | 1 | 2010 | 692 | 0.010 |
Why?
|
Probability | 1 | 2010 | 2475 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2016 | 1846 | 0.010 |
Why?
|
Sexuality | 1 | 2006 | 180 | 0.010 |
Why?
|
Mental Health | 1 | 2018 | 3251 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3797 | 0.010 |
Why?
|
Breast Diseases | 1 | 2006 | 443 | 0.010 |
Why?
|
Psychology | 1 | 2005 | 356 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7995 | 0.010 |
Why?
|
Treatment Failure | 1 | 2009 | 2635 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2005 | 15612 | 0.010 |
Why?
|
Family | 1 | 2013 | 3193 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2392 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2005 | 368 | 0.010 |
Why?
|
Russia | 1 | 2002 | 382 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15251 | 0.010 |
Why?
|
Body Image | 1 | 2006 | 639 | 0.010 |
Why?
|
Breast Implants | 1 | 2005 | 407 | 0.010 |
Why?
|
Stroke Volume | 1 | 2014 | 5486 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2007 | 2697 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1437 | 0.010 |
Why?
|
Cause of Death | 1 | 2010 | 3683 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2009 | 1790 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12043 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2012 | 11069 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12447 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6233 | 0.010 |
Why?
|
Databases, Factual | 1 | 2012 | 7960 | 0.010 |
Why?
|
Indomethacin | 1 | 1996 | 323 | 0.010 |
Why?
|
Aging | 1 | 1995 | 8699 | 0.010 |
Why?
|
Program Development | 1 | 2002 | 1293 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2012 | 4803 | 0.010 |
Why?
|
Chronic Disease | 1 | 2009 | 9311 | 0.010 |
Why?
|
France | 1 | 1996 | 492 | 0.010 |
Why?
|
Syndrome | 1 | 1996 | 3268 | 0.010 |
Why?
|
Birth Weight | 1 | 1996 | 2101 | 0.000 |
Why?
|
Pregnancy Outcome | 1 | 1996 | 2921 | 0.000 |
Why?
|